SBCVC
VC Fund
Shanghai, China
SBCVC is a VC fund in Shanghai focused on Health Care and Software. Established in 2000, SB China Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Their investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and they invest across all stages of companies. With extensive entrepreneurial and operating experiences, their professional and seasoned deal team members recognize the vision and champion the ideas of start-up companies. In addition to providing capital support, they help their portfolio companies realize their strategic and commercial potential by giving value-adding services and advices including planning, business development, recruiting and resources deployment. They have a proven track record and solid reputation in identifying high potential start-ups and creating successful industry-leading companies. Some of their spotlight portfolio companies are Alibaba, Taobao, Focus Media, GDS, BGI, Ankon, Di’an, and Edan. With their operational headquarters located in Shanghai and regional offices spread in Beijing, Shenzhen, Chengdu, Hangzhou and Taiwan, they have an extensive coverage of the greater China region and access to potential investment opportunities.
- Total investments:
- 136
- Last investment:
- Lead investor:
- 30%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SBCVC invests in
Stages SBCVC invests in
Countries SBCVC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $2M–$31M
- Series B
- $4.5M–$47M
- Series C
- $10M–$105M
Investment Focus
Industry
- Health Care 22 (16%)
- Software 17 (13%)
- Information Technology 16 (12%)
- Medical 15 (11%)
- Manufacturing 13 (10%)
Stage
- Series A 38 (28%)
- Series B 37 (27%)
- Series C 18 (13%)
- Angel 8 (6%)
- Venture - Series Unknown 8 (6%)
Country
- China 85 (63%)
- United States 6 (4%)
- Australia 4 (3%)
- Hong Kong 2 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan Song
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
Kathy Chen
Partner and CFO
|
Partner and CFO | Total investments: 1 | Find email | |
Tim Liu
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Chauncey Shey
Founder, Managing Partner & President
|
Founder, Managing Partner & President | Total investments: 1 | Find email | |
|
Guo Bin
Executive Director of Softbank China Capital
|
Executive Director of Softbank China Capital | Total investments: 1 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
UCaize
|
UCaize is a biopharmaceutical company that researches and develops novel medications for the treatment of blood cancers. | $11M / Seed / Feb 26, 2025 | |
| Guoke Tanmei is a visionary enterprise focused on developing materials for carbon-based energy storage. It directs at application scenarios including base stations, two-wheelers, electric cars, industrial cars, and energy storage. | Angel / Oct 25, 2023 | ||
| Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy. | Series D / Sep 28, 2023 | ||
| Shengyin Optoelectronics is a platform-based micro-nano manufacturing firm that creates ornamental films for electrical appliances and portable electronics. | $14.5M / Series A / May 05, 2023 | ||
| DeepWay is a maker and developer of intelligent electric commercial vehicles. | $111.8M / Series A / Mar 27, 2023 | ||
| Xindi Digital Engineering System specializes in the development of 3D CAD software for manufacturing enterprises. | $97.6M / Venture - Series Unknown / Oct 26, 2022 | ||
| HaploX Biotechnology is a Shenzhen-based genetic sequencing company. | Series D / Jul 26, 2022 | ||
| DPM's business scope includes several series of high-end intraoperative optical molecular imaging surgical navigation equipment and contrast agents developed and produced independently. Digital Precision Medical product lines are primate MPI-CT fusion, multimodal imaging system, near-infrared region ii, full spectrum, smart eye h280, 4Kfluorescence-hui yan h3800, and super eye c1000. The products are used for various surgical procedures and have the benefits of high sensitivity, high-definition fidelity, and ease of operation. | Series B / Jul 19, 2022 | ||
| Sunman Energy is a technology company founded by a group of industry veterans delivering the future of Solar. Through the research and development of composite materials, Sunman has successfully commercialized the world’s first glass-free, lightweight and flexible Panel – eArc. Replacing glass completely, eArc brings solar power to markets andapplication scenarios that were previously impossible. | $45M / Series C / Jul 01, 2022 | ||
| Lipps is a research and development, production and sales company of power semiconductor components. It can independently design IGBT/SIC, MOSFET modules and IPM module products, and has established a cooperative relationship with Japanese power module packaging factories. | $6.9M / Series A / Apr 01, 2022 | ||
| See all 136 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SBCVC invest in?
SBCVC invests primarily in Health Care, Software and Information Technology startups, most often at Series A and Series B stage. Most of the 136 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does SBCVC invest in?
SBCVC typically joins rounds of $2M–$31M at Series A, $4.5M–$47M at Series B and $10M–$105M at Series C. These are whole funding-round sizes, not SBCVC's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds SBCVC took part in.
How do I contact SBCVC?
Public channels for SBCVC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SBCVC?
The team at SBCVC includes Alan Song (Managing Partner), Kathy Chen (Partner and CFO) and Tim Liu (Managing Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
